Antag Therapeutics Doses First Patient in Phase 2a Trial of AT7687 for Obesity and Type 2 Diabetes
Wednesday, July 29, 2026
Antag Therapeutics has dosed the first participant in its Phase 2a clinical trial evaluating AT7687, a first-in-class glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist, in combination with semaglutide for the treatment of obesity and type 2 diabetes.
AT7687 is a peptide-based GIPR antagonist designed to block the GIP receptor, a genetically validated target linked to excess body fat, insulin resistance and cardiometabolic disease. The investigational therapy is intended to complement existing incretin-based treatments by targeting a different biological pathway, with the aim of improving metabolic health while maintaining good tolerability.
The Phase 2a study is a multicentre, randomised, double-blind, placebo-controlled trial that will enrol 150 adults with overweight or obesity and type 2 diabetes who are not currently receiving anti-obesity medicines. Participants will receive either a once-weekly subcutaneous injection of AT7687 alongside semaglutide dose escalation or placebo with semaglutide dose escalation over a 13-week treatment period, followed by a one-month safety follow-up.
The primary endpoint of the trial is the change in body weight from randomisation. The key secondary endpoint is the change in HbA1c levels. Additional secondary and exploratory endpoints will assess a range of biomarkers and clinical measures related to inflammation, metabolic health and long-term cardiovascular outcomes.
The study is being conducted at multiple sites across the United States, with topline results expected in the first half of 2027.
The Phase 2a programme follows positive Phase 1 results reported earlier this year. The earlier study demonstrated a favourable safety and tolerability profile across both single ascending dose and multiple ascending dose cohorts, with no severe or serious adverse events reported. The Phase 1 data also showed no gastrointestinal tolerability concerns, supporting further clinical development of AT7687 as a potential combination therapy for obesity and type 2 diabetes.
Source: globenewswire.com
